(MENAFN- GlobeNewsWire - Nasdaq) The global real world evidence (RWE) solutions market is set to expand from USD 5.42 billion in 2025 to USD 10.83 billion by 2030, with a CAGR of 14.8%. A shift towards value-based care and rising chronic disease prevalence drive this growth. RWE solutions, particularly in data sets, promote cost-efficient drug development, enhancing adoption across pharma and biotech firms. Post-market surveillance and the Asia Pacific region show significant potential, due to evolving regulations and clinical trials. Key industry players include IQVIA, Optum, and ICON Plc. The market's landscape will be shaped by advancements in RWE services, regulatory support, and emerging markets.

Dublin, Oct. 01, 2025 (GLOBE NEWSWIRE) -- The "Real World Evidence Solutions Market by Component (Datasets (Claims, Clinical, Pharmacy, Genomics), Application (Drug/Device Development (Cancer, Cardio, Neuro), Reimbursement), End User (Pharma, Medtech, Payers, Provider), Region - Global Forecast to 2030" report has been added to ResearchAndMarkets's offering.
The global real world evidence solutions market is projected to reach USD 10.83 billion by 2030 from USD 5.42 billion in 2025, at a CAGR of 14.8%

The market's growth is fueled by the transition to value-based care and the increasing incidence of chronic diseases. Real world evidence (RWE) can potentially reduce both costs and time in the drug development process. This has resulted in the growing adoption of RWE solutions across pharmaceutical & medical device companies.

By component, the data sets segment is expected to grow at the highest CAGR during the forecast period.
Based on component, the real world evidence solution market is segmented into services, data sets, and integrated data sets. The data sets segment is projected to grow at the highest CAGR during the forecast period. With the growing digitization of healthcare and increasing acceptance of real world data by regulators such as the FDA and EMA; the demand for high-quality, curated datasets, such as EHRs, claims, and registry data, has surged. These datasets power analytics, AI models, and health economics studies, making them critical assets for pharma, biotech, and healthcare companies. Additionally, their recurring revenue potential through licensing further drives their dominance in the RWE landscape.
By application, the post-market surveillance segment is expected to register the highest CAGR during the forecast period.
By application, the real world evidence solutions market is segmented into drug development & approvals, medical device development & approvals, post-market surveillance, market access & reimbursement decision-making, clinical & regulatory decision-making, and other applications. The post-market surveillance segment is expected to register the highest CAGR during the forecast period. The increasing regulatory focus on long-term safety and the efficacy of drugs & medical devices after market approval drives the high growth rate of this segment. Regulatory agencies such as the US FDA, the EMA, and the PMDA in Japan have emphasized monitoring real-world outcomes to identify adverse events, track product performance, and support risk management plans.
By end user, the pharmaceutical & biotechnology companies segment is projected to grow at the highest CAGR during the forecast period.
The RWE solutions market is segmented by end users into pharmaceutical & biotechnology companies, MedTech companies, healthcare payers, healthcare providers, and other end users. The pharmaceutical & biotechnological companies segment is projected to grow at the highest CAGR during the forecast period. The key factors contributing to market growth include adopting RWE solutions to decrease the costs & time for drug development, as RWE data provides clinical insights on the development of new drugs & medical devices. The high growth in the pharmaceutical industry is also an additional factor, fueling the adoption of real world solutions.
The Asia Pacific region is projected to register the highest CAGR during the forecast period.
The market is segmented by region into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The RWE solutions market in the Asia Pacific region is projected to register the highest CAGR during the forecast period. The high growth rate of this region is attributed to the rising initiatives towards adopting RWE by pharmaceutical & medical device companies. This rapid expansion is driven by the high volume of clinical trials undertaken by emerging economies such as China, India, Japan, and South Korea, along with evolving regulatory frameworks that are beginning to accept RWE for drug approvals and post-market surveillance.

Key Attributes:

Report Attribute	Details
No. of Pages	377
Forecast Period	2025 - 2030
Estimated Market Value in 2025	5.42 Billion
Forecasted Market Value by 2030	10.83 Billion
Compound Annual Growth Rate	14.8%
Regions Covered	Global

Market Dynamics

Drivers

• Rising Geriatric Population and Subsequent Increase in Prevalence of Chronic Diseases
• Shift from Volume-based Care to Value-based Care
• Potential of Real World Evidence in Reducing Drug Development Costs and Expediting Drug Development Process
• Increased R&D Spending for Development of New Pharmaceutical Products and Medical Devices
• Support from Regulatory Bodies for Use of Real World Evidence Solutions

Restraints

• Reluctance of Medical Practitioners and Researchers to Rely on Real World Studies
• Data Quality and Standardization Issues

Opportunities

• Growth Opportunities in Emerging Markets
• Increased Focus on End-To-End Rwe Services
• Increased Focus on Personalized and Precision Medicine
• Market Access, Health Technology Assessment (Hta), and Reimbursement

Challenges

• Lack of Universally Accepted Methodology Standards and Data Processing Infrastructure
• Shortage of Skilled Professionals

Industry Trends

• Emerging Role of Wearable Devices
• Social Media-Sourced Rwe
• Rising Use of Rwd and Rwe Across Pharmaceutical Industry
• Rwe Analytics Approach: Internal vs. Outsourced
• Incorporation of Artificial Intelligence into Rwd Management

Case Study Analysis

• Designing and Building Rwe Dashboards and Leveraging Ehr and Claims Data
• Integrating Specialty Pharmacy and Patient Hub Data with Rwd Data to Investigate into Non-Adherence Factors
• Simplifying Data Analytics with Rwe Platform

Real World Evidence Solutions Market: Business Models

• Platform-As-A-Service (PaaS) Model
• Data Provider Model
• Consulting and Services Model
• Collaborative Research Model

Technology Analysis

• Key Technologies
• Use of AI and ML
• Blockchain Technology
• Adjacent Technologies
• Predictive Analytics
• Visualization Dashboard Software
• Complementary Technologies
• Electronic Health Records (Ehrs)
• Clinical Trial Management System

Company Profiles

• Iqvia
• Merative
• Optum, Inc.
• Icon PLC
• Syneos Health
• Parexel International (Ma) Corporation
• Flatiron Health
• Fortrea
• Oracle
• Elevance Health
• Sas Institute Inc.
• Aetion, Inc.
• Trinetx, LLC
• Trinity
• Medidata
• Cognizant Technology Solutions Corporation
• Cegedim Health Data
• Verantos
• Medpace
• Tata Consultancy Services Limited
• Healthverity, Inc.
• Om1
• Open Health
• Tempus
• Quantzig

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment

• Real World Evidence Solutions Market

CONTACT: CONTACT: Laura Wood,Senior Press Manager ... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN01102025004107003653ID1110137409